Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00636064 · ClinicalTrials.gov registry record · Phase 3
A Study Comparing the Efficacy and Safety of Valdecoxib Plus Parecoxib Versus Valdecoxib Plus Placebo for the Treatment of Pain After Coronary Artery Bypass Surgery
A Phase 3 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,671
- Enrollment target
NCT00636064 is a Phase 3 study that has completed, run by Pfizer. The registered enrollment target is 1,671 participants.
The verdict
NCT00636064, a Phase 3 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,671 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of parecoxib/valdecoxib therapy and placebo/valdecoxib therapy for the treatment of pain after coronary artery bypass surgery
Interventions
- DRUG Parecoxib Sodium/Valdecoxib
- DRUG Placebo/Valdecoxib
- OTHER Placebo/Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,671 participants |
| Start Date | 2003-01 |
| Est. Completion | 2004-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00636064
The ClinicalTrials.gov registry entry for NCT00636064 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,671 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Parecoxib Sodium/Valdecoxib is the first listed.
NCT00636064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00636064 about?
NCT00636064 is a clinical study titled "A Study Comparing the Efficacy and Safety of Valdecoxib Plus Parecoxib Versus Valdecoxib Plus Placebo for the Treatment of Pain After Coronary Artery Bypass Surgery". The purpose of this study is to evaluate the efficacy and safety of parecoxib/valdecoxib therapy and placebo/valdecoxib therapy for the treatment of pain after coronary artery bypass surgery
What is the current status of trial NCT00636064?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,671 participants. The study started on 2003-01. Estimated completion is 2004-01.
What interventions are being tested in trial NCT00636064?
The interventions under investigation include: Parecoxib Sodium/Valdecoxib (DRUG), Placebo/Valdecoxib (DRUG), Placebo/Placebo (OTHER).
Who is sponsoring clinical trial NCT00636064?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.